'In healthy menstruation the blood which is discharged does not coagulate; in the irregular or unhealthy it does....' This observation on the non-coagulability of menstrual blood was made by John Hunter in 1794.1 A similar observation was made by Bell in 19122 on the composition of menstrual blood found in patients with haematocolpos. Over the past 20 years laboratory and clinical research has established that fibrinolysis is intimately concerned with the process of menstruation. The early studies of plasminogen activator showed high concentrations present in both the uterus and menstrual discharge.3 4 Extracts of secretory endometrium and endometrium from women with endometrial hyperplasia contained large amounts of activator. This established that the fluidity of menstrual blood was due to fibrin dissolution by plasmin produced by the activators of plasminogen. In a review offibrinolysis Astrup5 suggested that increased local fibrinolytic activity might be the cause of excessive menstrual bleeding. This was supported by the findings of high concentrations of tissue activator in the fibrinolytic enzyme system not only in the endometrium but also in the myometrium of the uterus and in the glands of the cervical canal.6 7 In a study of patients with excessive menstrual loss measured by an objective method, Rybo 14 and tranexamic acid (AMCA) was also found to be effective. '5-17 Treating menorrhagia with EACA, AMCA, or PAMBA, Nilsson and Rybo18 found that menstrual loss was reduced by 49 %, 53 %, and 36% respectively when measured by the alkaline haematin method. The dose of AMCA was 3-6 g/day for four days, starting after the onset of menstruation. Bleeding in pregnancy is associated with a substantial increase in perinatal mortality. Studies of the uteroplacental arteries have shown that fibrin deposition is a physiological component of the walls of the spiral arteries in late pregnancy25 (Fig. 3) . The fibrinolytic activity of the vessel is also inhibited near the trophoblast cells present in the terminal parts of the spiral arteries26 (Fig. 4) . Bleeding from the placental site in normally situated placentas may result from structural weakness and vascular defects due to defective fibrin deposition in some of the uteroplacental vessels. The use of a fibrinolytic inhibitor may therefore improve haemostasis at the placental site by augmenting the naturally occurring fibrinolytic inhibition produced by the placenta.
An effective method of treating placental bleeding in pregnancy might lower the high associated perinatal mortality and morbidity by reducing placental damage due to the bleeding and the incidence of premature labour. We have set up a strictly controlled trial in the Rotunda Hospital to evaluate the benefit of treatment with the fibrinolytic inhibitor tranexamic acid to the mother and to the baby when placental bleeding occurs between the 16-37th week of pregnancy.
GYNAECOLOGICAL MALIGNANCY
In a few patients with cervical and uterine carcinoma profuse bleeding may occur which does not respond to local haemostatic measures. EACA or AMCA can be used for the short-term control of such bleeding. In patients with ovarian carcinoma high concentra-tions of FDP are present which usually reflect the progress of the disease. The contribution of fibrinolysis to the spread of carcinoma in such tumours requires detailed research.
SIDE EFFECTS OF FIBRINOLYTIC INHIBITORS
The main problem of treatment with fibrinolytic inhibitors has been the side effects. Their incidence during treatment with EACA in 83 women treated over six months is shown in Table 2 . Six women discontinued treatment because of the severity of the side effects. If the fibrinolytic inhibitor were given per vaginum or per rectum the incidence of gastrointestinal side effects might be reduced. This requires further investigation. The incidence of side effects with tranexamic acid seem to be much less than with EACA. 
